Cosmo Pharmaceuticals (OTCMKTS:CMOPF) Short Interest Down 32.4% in August

Cosmo Pharmaceuticals (OTCMKTS:CMOPF) saw a large drop in short interest in August. As of August 31st, there was short interest totaling 7,450 shares, a drop of 32.4% from the August 15th total of 11,024 shares. Based on an average trading volume of 447 shares, the short-interest ratio is presently 16.7 days.

Cosmo Pharmaceuticals Stock Performance

Shares of Cosmo Pharmaceuticals stock opened at C$67.28 on Friday. Cosmo Pharmaceuticals has a 1 year low of C$63.49 and a 1 year high of C$169.90. The firm’s 50-day simple moving average is C$73.26 and its 200-day simple moving average is C$92.26.

Cosmo Pharmaceuticals Company Profile

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.